عضویت در سایت

Davood Khalili


Davood Khalili

 

 

Date Prepared:

Jun 2019

Office Address:

Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, No. 23, Arabi st, Velenjak, Tehran, Iran

Cell Phone:

+98 9128148865

Academic Email:

dkhalili@endocrine.ac.ir ; dkhalili@hsph.harvard.edu

https://isid.research.ac.ir/Davoud_Khalili

 

Education

 

Official degrees:

Year

Degrees

Fields of Study

Institution

2012

Medical Specialty (MD, PhD)

Epidemiology

Shahid Beheshti University of Medical Sciences, Tehran

2008

Master (MPH)

Public Health

Shahid Beheshti University of Medical Sciences, Tehran

1998

MD

Medicine

Urmia University of Medical Sciences, Urmia, Iran

 

 

Other advanced training

Year

Fields of Study

Institution

2019

Clinical Genomics

31st Course jointly organized by ESGM, ESHG, and CEUB

2016

Iran Diabetes Advancement in Research

The American Association of Continuing Medical Education, Sanofi Group Middle East

2011

Epidemiology and Biostatistics

Erasmus Summer Program, Erasmus MC University, Rotterdam, The Netherlands

2011

Recent Developments in Epidemiologic Research

International Epidemiological Association, Edinburgh, Scotland

 

PhD Thesis:

Validation, Recalibration and Clinical Usefulness of the Framingham Risk Function for Cardiovascular Diseases in an Iranian Population.

 

 

 

Academic Appointments

 

Faculty member:

Month/Year(s)

Academic Title

Department

Institution

2019 -

Associate Professor

Prevention of Metabolic Disorders Research Center

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran

2013 -2018

Assistant Professor

Prevention of Metabolic Disorders Research Center

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran

 

Other Affiliated Institutions:

Month/Year(s)

Position Title

Department

(Division, if applicable)

Institution

2017 -

Lown Scholar

Department of Global Health and Population

Harvard T.H. Chan School of Public Health, Boston, MA

2017

Visiting Scholar

Department of Biomedical Data Sciences

Leiden University Medical Center (LUMC), The Netherlands

2016 -

Adjunct Professor

Department of Epidemiology

School of Public Health, Iran University of Medical Sciences

 

Other Professional Positions:

Year(s)

Position Title

Institution

Level of effort

2016-2017, 2019

Consultant

World Health Organization

By project

2016-2018

International Advisory board

The Middle East, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA)

Annual meetings

2016-2018

Board member

The Scientific Association for Public Health in Iran (SAPHIR)

Monthly meetings

2013 -

Advisory board

Clinical Trial Center, Tehran University of Medical Sciences

Annual meetings & monthly journal clubs

 

 

Major Administrative Leadership Positions

 

Local

Year(s)

Position Title

Institution (note if specific department)

2015-

Director

Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, Tehran

2012-2015

Research manager

Research Deputy, Research Institute for Endocrine Sciences, Tehran

 

National

 

2014-

Secretary-General

Iran Cohort Consortium

 

Committee Service:

 

Local

Year(s)

Name of Committee

Institution/Organization

2012 -           

Member, Institutional Review Board committee

Research Institute for Endocrine Sciences

National

Year(s)

Name of Committee

Institution/Organization

2016 -           

Member, Council of education and research

Iran Cohort Consortium

 

 

Clinical Practice:

 

Year(s)

Type of activity

Name and location of the practice

1999-2001

General Practitioner

Emergency unite, Manjil Hospital, Guilan province, Iran

2001-2007

General Practitioner

Urban & rural health centers, Guilan province, Iran

 

During these years I had the opportunity to acquire firsthand experience of primary and secondary care in a variety of urban and rural settings which helped me to identify the gaps and shaped and informed my future research career.

         

 

 

 

Editorial Activities

  • Ad hoc Reviewer:

List of journals

  • The Lancet
  • The Lancet Global Health
  • Annals of Internal Medicine
  • PLOS Medicine
  • American Journal of Cardiology
  • Journal of Clinical Epidemiology
  • PLOS ONE
  • BMC journals
  • Preventive Medicine
  • Lipids in Health and Disease
  • International Journal of Information Technology & Decision Making
  • Archives of Iranian Medicine
  • Asia Pacific Journal of Cancer Prevention
  • Journal of Research in Health Sciences
  • Journal of Diabetes & Metabolic Disorders
  • The Journal of Tehran Heart Center
  • Iranian Journal of Epidemiology

 

 

  • Editorial Roles:

Year(s)

Role

Journal/Publication Title

2014 -

Associate editor

International Journal of Endocrinology and Metabolism

2014 -

Associate editor

Iranian Journal of Endocrinology and Metabolism

 

Other Review Activities

National research Grant / Audit

 

2019 -

WHO STEPS survey committee

Ad hoc reviewer, National Institute of Health Research

2017 -

Non-Communicable Diseases committee

Ad hoc Member, National Institute for Medical Research Development (NIMAD)

 

 

Honors and Prizes:

 

2019

A letter of appreciation

Ministry of Health and Medical Education

For an elaborate review and evaluation of some research centers

2017

Honor researcher

Shahid Beheshti University of Medical Sciences, Tehran

Ranked first among assistant professors in the University

2015

Excellent Scientist

Vice-Presidency for Science and Technology, Iran

Among top 100 researchers

2011

Honor researcher

Shahid Beheshti University of Medical Sciences, Tehran

Ranked first among non-faculty members in the University

2009

Honor PhD student

Shahid Beheshti University of Medical Sciences, Tehran

Ranked first among PhD students in the school of public health

2008

Honor PhD student

Shahid Beheshti University of Medical Sciences, Tehran

Ranked first among PhD students in the school of public health

2009

A letter of appreciation

Ministry of Health and Medical Education

For contribution in the construction of Iranian Registry of Clinical Trials as a primary registry of WHO

2000

Honor researcher

Guilan University of Medical Sciences, Rasht, Iran

Among the best researchers in the University

 

 

 

Funded Projects

During the past 3 years

Year(s)

Grant title

 

2017

Updating diabetes risk scoring for the Iranian population, WHO, PI

 

2017

Situation analysis to Implement adapted tools in the demonstration site of HEART initiatives in Iran, WHO, PI

 

2017

Long-term effectiveness of a community-based field trial targeting lifestyle and education interventions on the incidence of type 2 diabetes and metabolic syndrome. Research Institute for Endocrine Sciences, PI

2016

Developing Iran Cohort Consortium,  PI

2016

Providing metadata for Tehran Lipid and Glucose Study. Research Institute for Endocrine Sciences, PI

2016

Updating CVD risk scoring for implementation in primary health care based on updated CVD risk score, WHO recommendations and country circumstances, WHO, PI

2015

Comprehensive Monitoring and Evaluation of Screening Program for Congenital Hypothyroidism, Research Institute for Endocrine Sciences, Co-PI

 

Current

Year(s)

Grant title

2019

To develop a pilot plan for IraPEN program and a no-lab prediction model for assessment of NCDs risk factors, WHO, PI, $25000

2018

Cost-effectiveness of the risk-based prevention of cardiovascular diseases in primary health care: National Institute for Medical Research Development (NIMAD), Iran, PI,  756,000,000 Rials by NIMAD and $10,118 by Harvard T.H. Chan School of Public Health

2018

To study the trend of risk for cardiovascular diseases during the past decade and estimate the incidence of these diseases during the next decade in Iran, National Institute for Medical Research Development (NIMAD), PI, 275,000,000 Rials

2018

Validation of the American Diabetes Association (ADA) diabetes screening score in an Iranian population: Its diagnostic and prognostic power, National Institute for Medical Research Development (NIMAD), PI, 275,000,000 Rials

     

 

 

Other funded projects and all unfunded ones, resulted in original articles, are presented as publications in peer-reviewed journals.

Teaching and Training

Teaching of Students in Courses:

Year(s)

Course Title

Location

2016-

Clinical prediction models, for PhD students in epidemiology

Department of Epidemiology, Iran University of Medical Sciences, Tehran

2017-

Advanced research methodology, for PhD by research students and physician-scientists

Shahid Beheshti University of Medical Sciences, Tehran

 

Formal Teaching of Residents and Fellows:

Year(s)

Title

Location

2015-

Research Methodology for residents and fellows

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran

Research Supervision of Students and Fellows:

Year(s)

Title of Thesis/Dissertation

Location

2019 -

Determination of trajectory of metabolic risk factors and biomarkers in patients with prediabetes prior to the development of diabetes

Co-supervisor, Endocrinology Fellow, Research Institute for Endocrine Sciences, Tehran

2019 -

The association of insulin resistance and beta-cell dysfunction with prediabetes and determination of a cut-off point for HOMA-IR and HOMA-B to predict prediabetes

Co-supervisor, Endocrinology Fellow,  Research Institute for Endocrine Sciences, Tehran

2019 -

Application of dynamic prediction models for three-year incident dysglycemia and type 2 diabetes using Joint modeling of longitudinal and time-to-event data in population-based cohorts

Co-supervisor, PhD student, Research Institute for Endocrine Sciences, Tehran

2019 -

The risk threshold for initiating cardiovascular preventive therapy based on the evidence-based decision-making model

Co-supervisor, PhD students, Department of Epidemiology, Iran University of Medical Sciences, Tehran

2018 -

A cost-effectiveness analysis of risk-based intervention for the prevention of cardiovascular disease in IraPEN: A pilot study in Iran

Co-supervisor, MS student, University of Oslo, Norway

2017 -

The net benefit of using Globorisk risk score to identify high-risk individuals for cardiovascular diseases

Co-supervisor, PhD students, Department of Epidemiology, Iran University of Medical Sciences, Tehran

2016 -

Effectiveness of lifestyle intervention programs for type 2 diabetes prevention in resource-constrained settings

Co-supervisor, PhD student, Non-Communicable Disease Control Unit (NCDU), University of Melbourne, Australia

2016-2018

Comprehensive Monitoring and Evaluation of Screening Program for Congenital Hypothyroidism

Co-supervisor, PhD student, Research Institute for Endocrine Sciences, Tehran

2016-2018

Determining a national risk function to predict cardiovascular diseases mortality using the pooled data of population-based cohorts and surveys of Iran

Co-supervisor, PhD student, Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran

2015-2017

Assessment of lifestyle pattern among Iranian population using Self-organizing map and Latent class cluster analysis methods and its association with blood pressure

Co-supervisor, PhD student, Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran

2015-2016

The latent classes of metabolic syndrome components and the effect of the intervention program on changing these classes over time

Supervisor, MS student, Department of Epidemiology, Shahid Beheshti University University of Medical Sciences, Tehran

       

 

Invited Presentations

Year(s)

Title of presentation / Location

Local & National

 

2012-2018

At least 10 local & national invited talks regarding cohort studies, prediction models and cardiometabolic risk factors in Iran

Regional

 

2016

The situation of cardiovascular diseases in Africa and Middle East. Middle East, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA) Forum. Abu Dhabi, United Arab Emirates

2017

WHO Package of Essential Noncommunicable (PEN) disease interventions for primary health care. Middle East, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA) Forum. Cairo, Egypt (However, I was unable to attend because of visa)

 

 

 

Publications in Peer-Reviewed Journals

 

  1. Azizi F, Hadaegh F, Hosseinpanah F, Mirmiran P, Amouzegar A, Abdi H, Asghari G, Parizadeh D, Montazeri SA, Lotfaliany M, Takyar F, Khalili D*. Metabolic Health in the Middle East and North Africa Region. Lancet Diabetes Endocrinol. 2019 (Accepted)
  2. Danaei G, Farzadfar F, Kelishadi R, Rashidian A, Rouhani OM, Ahmadnia S, Ahmadvand A, Arabi M, Ardalan A, Arhami M, Azizi MH, Bahadori M, Baumgartner J, Beheshtian A, Djalalinia S, Doshmangir L, Haghdoost AA, Haghshenas R, Hosseinpoor AR, Islami F, Kamangar F, Khalili D, Madani M, Masoumi-Asl H, Mazyaki A, Mirchi A, Moradi E, Nayernouri T, Niemeier D, Omidvari AH, Peykari N, Pishgar F, Qorbani M, Rahimi K, Rahimi-Movaghar A, Tehrani FR, Rezaei N, Shahraz S, Takian A, Tootee A, Ezzati M, Jamshidi HR, Larijani B, Majdzadeh R, Malekzadeh R. Iran in transition. Lancet. 2019 May 11;393(10184):1984-2005.
  3. NCD Risk Factor Collaboration (NCD-RisC). Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature. 2019 May;569(7755):260-264.
  4. Khajavi A, Khalili D, Azizi F, Hadaegh F. Impact of temperature and air pollution on cardiovascular disease and death in Iran: A 15-year follow-up of Tehran Lipid and Glucose Study. Sci Total Environ. 2019 Apr 15;661:243-250
  5. Lotfaliany M, Hadaegh F, Asgari S, Mansournia MA, Azizi F, Oldenburg B, Khalili D*. Non-invasive Risk Prediction Models in Identifying Undiagnosed Type 2 Diabetes or Predicting Future Incident Cases in the Iranian Population. Arch Iran Med. 2019 Mar 1;22(3):116-124.
  6. Khalili D, Asgari S, Lotfaliany M, Zafari N, Hadaegh F, Momenan AA, Nowroozpoor A, Hosseini-Esfahani F, Mirmiran P, Amiri P, Azizi F. Long-Term Effectiveness of a Lifestyle Intervention: A Pragmatic Community Trial to Prevent Metabolic Syndrome. Am J Prev Med. 2019 Mar;56(3):437-446.
  7. Mehran L, Khalili D, Yarahmadi S, Delshad H, Mehrabi Y, Amouzegar A, Ajang N, Azizi F. Evaluation of the congenital hypothyroidism screening programme in Iran: a 3-year retrospective cohort study. Arch Dis Child Fetal Neonatal Ed. 2019 Mar;104(2):F176-F181.
  8. Ahanchi NS, Hadaegh F, Alipour A, Ghanbarian A, Azizi F, Khalili D*. Application of Latent Class Analysis to Identify Metabolic Syndrome Components Patterns in adults: Tehran Lipid and Glucose study. Sci Rep. 2019 Feb 7;9(1):1572.
  9. Amiri P, Vahedi-Notash G, Naseri P, Khalili D, Hashemi Nazari SS, Mehrabi Y, Mahdavi Hazaveh AR, Azizi F, Hadaegh F. National trends of pre-hypertension and hypertension among Iranian adolescents across urban and rural areas (2007-2011). Biol Sex Differ. 2019 Mar 29;10(1):15.
  10. Farahmand M, Ramezani Tehrani F, Khalili D, Cheraghi L, Bahri Khomami M, Azizi F. Association between duration of endogenous estrogen exposure and cardiovascular outcomes: A population - based cohort study. Life Sci. 2019 Mar 15;221:335-340.
  11. Khalili D, Azizi F, Asgari S, Zadeh-Vakili A, Momenan AA, Ghanbarian A, Eskandari F, Sheikholeslami F, Hadaegh F. Outcomes of a Longitudinal Population-based Cohort Study and Pragmatic Community Trial: Findings from 20 Years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018 Oct; 16(4 Suppl):e84748.
  12. Akbarpour S, Khalili D, Zeraati H, Mansournia MA, Ramezankhanim A, Fotouhi A. Lifestyle patterns in the Iranian population: Self- organizing map application. Caspian J Intern Med. 2018 Summer;9(3):268-275.
  13. Ramezankhani A, Harati H, Bozorgmanesh M, Tohidi M, Khalili D, Azizi F, Hadaegh F. Diabetes Mellitus: Findings from 20 Years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018 Oct 16;16(4 Suppl):e84784.
  14.  Lotfaliany M, Akbarpour S, Zafari N, Mansournia MA, Asgari S, Azizi F, Hadaegh F, Khalili D*. World Bank Income Group, Health Expenditure or Cardiometabolic Risk Factors? A Further Explanation of the Wide Gap in Cardiometabolic Mortality Between Worldwide Countries: An Ecological Study. Int J Endocrinol Metab. 2018 Jul; 16(3):e59946.
  15. Fahimfar N, Khalili D, Sepanlou SG, Malekzadeh R, Azizi F, Mansournia MA, Roohafza H, Emamian MH, Hadaegh F, Poustchi H, Mansourian M, Hashemi H, Sharafkhah M, Pourshams A, Farzadfar F, Steyerberg EW, Fotouhi A. Cardiovascular mortality in a Western Asian country: results from the Iran Cohort Consortium. BMJ Open. 2018 Jul 5;8(7):e020303.
  16. Zafari N, Lotfaliany M, Mansournia MA, Khalili D, Azizi F, Hadaegh F. Optimal cut-points of different anthropometric indices and their joint effect in prediction of type 2 diabetes: results of a cohort study. BMC Public Health. 2018 Jun 5;18(1):691.
  17. Bakhtiyari M, Schmidt N, Hadaegh F, Khalili D, Mansournia N, Asgari S, Mansournia MA. Direct and indirect effects of central and general adiposity on cardiovascular diseases: The Tehran Lipid and Glucose Study. Eur J Prev Cardiol. 2018 Jul;25(11):1170-1181.
  18. Akbarpour S, Khalili D, Zeraati H, Mansournia MA, Ramezankhani A, Fotouhi A. Healthy lifestyle behaviors and control of hypertension among adult hypertensive patients. Sci Rep. 2018 May 31;8(1):8508.
  19. Rabani S, Sardarinia M, Akbarpour S, Azizi F, Khalili D, Hadaegh F. 12-year trends in cardiovascular risk factors (2002-2005 through 2011-2014) in patients with cardiovascular diseases: Tehran lipid and glucose study. PLoS One. 2018 May 16;13(5):e0195543.
  20. Amiri P, Jalali-Farahani S, Akbar HM, Cheraghi L, Khalili D, Momenan A, Mirmiran P, Ghanbarian A, Hedayati M, Hosseini-Esfahani F, Azizi F. The Effects of a Community-Based Lifestyle Intervention on Metabolic Syndrome and Its Components in Adolescents: Findings of a Decade Follow-Up. Metab Syndr Relat Disord. 2018 Jun;16(5):215-223.
  21. Asgari S, Abdi H, Hezaveh AM, Moghisi A, Etemad K, Beni HR, Khalili D*. The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors. Sci Rep. 2018 Mar 21;8(1):4928
  22. Mehran L, Khalili D, Yarahmadi S, Delshad H, Mehrabi Y, Amouzegar A, Ajang N, Azizi F. Evaluation of the congenital hypothyroidism screening programme in Iran: a 3-year retrospective cohort study. Arch Dis Child Fetal Neonatal Ed. 2018 Mar 14. pii: fetalneonatal-2017-313720.
  23. Kabootari M, Asgari S, Mansournia MA, Khalili D, Valizadeh M, Azizi F, Hadaegh F. Different Weight Histories and Risk of Incident Coronary Heart Disease and Stroke: Tehran Lipid and Glucose Study. J Am Heart Assoc. 2018 Feb 10;7(4). pii: e006924.
  24. Kazemi Jaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Hosseinpanah F, Khalili D, Cheraghi L, Azizi F. Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women: a long-term population-based follow-up study. Fertil Steril. 2017 Dec;108(6):1078-1084.
  25. Mehran L, Khalili D, Yarahmadi S, Amouzegar A, Mojarrad M, Ajang N, Azizi F. Worldwide Recall Rate in Newborn Screening Programs for Congenital Hypothyroidism. Int J Endocrinol Metab. 2017 Jun 25;15(3):e55451.
  26. Gilani N, Kazemnejad A, Zayeri F, Hadaegh F, Azizi F, Khalili D. Anthropometric Indices as Predictors of Coronary Heart Disease Risk: Joint Modeling of Longitudinal Measurements and Time to Event. Iran J Public Health. 2017 Nov;46(11):1546-1554.
  27. Amiri P, Jalali-Farahani S, Masihay Akbar H, Cheraghi L, Khalili D, Momenan A, Mirmiran P, Ghanbarian A, Hedayati M, Hosseini-Esfahani F, Azizi F. The Effects of a Community-Based Lifestyle Intervention on Metabolic Syndrome and Its Components in Adolescents: Findings of a Decade Follow-Up. Metab Syndr Relat Disord. 2018 Apr. [Epub ahead of print]
  28. Saeed Kalantari, Davood Khalili *, Samaneh Asgari, Noushin Fahimfar, Farzad Hadaegh, Maryam Tohidi and Fereidoun Azizi. Predictors of early adulthood hypertension during adolescence: a population-based cohort study. BMC Public Health 2017 17:915
  29. Mehran L, Yarahmadi S, Khalili D, Nazeri P, Delshad H, Abdollahi Z, Azhang N, Azizi F. The Impact of Iodine Status on the Recall Rate of the Screening Program for Congenital Hypothyroidism: Findings from Two National Studies in Iran. Nutrients. 2017 Oct 30;9(11).
  30. Taravatmanesh S, Khalili D, Khodakarim S, Asgari S, Hadaegh F, Azizi F, Sabour S. Determining the Factors Associated with Cardiovascular Disease Recurrence: Tehran Lipid and Glucose Study. J Tehran Heart Cent. 2017 Jul;12(3):107-113.
  31. Kazemijaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Khalili D, Hosseinpanah F, Azizi F. A Population-Based Study of the Prevalence of Abnormal Uterine Bleeding and its Related Factors among Iranian Reproductive-Age Women: An Updated Data. Arch Iran Med. 2017 Sep;20(9):558-563.
  32. Amiri M, Nahidi F, Khalili D, Bidhendi-Yarandi R, Ramezani Tehrani F. Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol. JMIR Res Protoc. 2017 Sep 29;6(9):e191.
  33. Mansournia MA, Holakouie-Naieni K, Fahimfar N, Almasi-Hashiani A, Cheraghi Z, Ayubi E, Hadaegh F, Eskandari F, Azizi F, Khalili D*. Risk of Coronary Heart Events Based on Rose Angina Questionnaire and ECG Besides Diabetes and Other Metabolic Risk Factors: Results of a 10-Year Follow-up in Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2017 Apr 24;15(2):e42713.
  34. Farahmand M, Ramezani Tehrani F, Khalili D, Amin G, Negarandeh R. Factors associated with the severity of premenstrual syndrome among Iranian college students. J Obstet Gynaecol Res. 2017 Nov;43(11):1726-1731.
  35. Ramezankhani A, Bagherzadeh-Khiabani F, Khalili D, Azizi F, Hadaegh F. A new look at risk patterns related to coronary heart disease incidence using survival tree analysis: 12 Years Longitudinal Study. Sci Rep. 2017 Jun 12;7(1):3237.
  36. Daneshpour MS, Fallah MS, Sedaghati-Khayat B, Guity K, Khalili D, Hedayati M, Ebrahimi A, Hajsheikholeslami F, Mirmiran P, Ramezani Tehrani F, Momenan AA, Ghanbarian A, Amouzegar A, Amiri P, Azizi F. Rationale and Design of a Genetic Study on Cardiometabolic Risk Factors: Protocol for the Tehran Cardiometabolic Genetic Study (TCGS). JMIR Res Protoc. 2017 Feb 23;6(2):e28.
  37. Peter Ueda,Mark Woodward, Yuan Lu, Kaveh Hajifathalian, Rihab Al-Wotayan, Carlos A Aguilar-Salinas, Alireza Ahmadvand, Fereidoun Azizi, James Bentham, Renata Cifkova, Mariachiara Di Cesare, Louise Eriksen, Farshad Farzadfar, Trevor S Ferguson, Nayu Ikeda, Davood Khalili, Young-Ho Khang, Vera Lanska, Luz León-Muñoz, Dianna Magliano, Paula Margozzini, Kelias P Msyamboza, Gerald N Mutungi, Kyungwon Oh, Sophal Oum, Fernando Rodríguez-Artalejo, Rosalba Rojas-Martinez, Gonzalo Valdivia, Rainford Wilks, Jonathan E Shaw, Gretchen A Stevens, Janne Tolstrup, Bin Zhou, Joshua A Salomon, Majid Ezzati, Goodarz Danaei.  Laboratory-based and office-based cardiovascular risk scores and charts for prediction of 10-year risk of fatal and non-fatal cardiovascular disease in 182 countries: a pooled analysis.  Lancet Diabetes Endocrinol. 2017 Mar;5(3):196-213.
  38. Golozar A, Khalili D, Etemadi A, Poustchi, Fazeltabar, Hosseini , Kamangar F, Khoshnia M, Islami F, Hadaegh F, Brennan P, Boffetta P, Abnet CC, Dawsey SM, Azizi F, Malekzadeh R, Danaei G. White rice intake and incidence of type-2 diabetes: analysis of two prospective cohort studies from Iran. BMC Public Health. 2017, 31;17(1):133.
  39. Barzin M, Motamedi MA, Serahati S, Khalaj A, Arian P, Valizadeh M, Khalili D, Azizi F, Hosseinpanah F.  Comparison of the Effect of Gastric Bypass and Sleeve Gastrectomy on Metabolic Syndrome and its Components in a Cohort: Tehran Obesity Treatment Study (TOTS). Obes Surg. 2017 2017 Jul;27(7):1697-1704
  40. Eslami A, Mozaffary A, Derakhshan A, Azizi F, Khalili D, Hadaegh F. Sex-specific incidence rates and risk factors of premature cardiovascular disease. A long term follow up of the Tehran Lipid and Glucose Study. Int J Cardiol. 2017. 15;227:826-832. 
  41. Asgari S, Barzin M, Hosseinpanah F, Hadaegh F, Azizi F, Khalili D*. Obesity Paradox and Recurrent Coronary Heart Disease in a Population-Based Study: Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2016 Apr 16;14(2). 
  42. Panahi MH, Hadaegh F, Yavari P, Kazempour-Ardebili S, Mehrabi Y, Azizi F, Khalili D*.  A Challenging Interaction of Chronic Kidney Disease With Other Metabolic Disorders: Paradoxes in Cardiometabolic Risk Factors. Iran J Kidney Dis. 2016 Sep;10(5):274-281.
  43. Cheraghi Z, Mirmiran P, Mansournia MA, Moslehi N, Khalili D, Nedjat S. The association between nutritional exposures and metabolic syndrome in the Tehran Lipid and Glucose Study (TLGS): a cohort study. Public Health. 2016;140:163-171.
  44. NCD Risk Factor Collaboration (NCD-RisC). A century of trends in adult human height. Elife. 2016 Jul 26;5.
  45. Shaseb E, Tohidi M, Abbasinazari M, Khalili D, Talasaz AH, Omrani H, Hadaegh F. The effect of a single dose of vitamin D on glycemic status and C-reactive protein levels in type 2 diabetic patients with ischemic heart disease: a randomized clinical trial. Acta Diabetol. 2016 Aug;53(4):575-82.
  46. Ghasemzadeh Z, Abdi H, Asgari S, Tohidi M, Khalili D, Valizadeh M, Moeini S, Eidkhani V, Azizi F, Hadaegh F. Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population. Nutr Metab (Lond). 2016 Jun 24;13:43.
  47. Helgadottir A, Gretarsdottir S, Thorleifsson G, Hjartarson E, Sigurdsson A, Magnusdottir A, Jonasdottir A, Kristjansson H, Sulem P, Oddsson A, Sveinbjornsson G, Steinthorsdottir V, Rafnar T, Masson G, Jonsdottir I, Olafsson I, Eyjolfsson GI, Sigurdardottir O, Daneshpour MS, Khalili D, Azizi F, Swinkels DW, Kiemeney L, Quyyumi AA, Levey AI, Patel RS, Hayek SS, Gudmundsdottir IJ, Thorgeirsson G, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson K. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature Genetics. 2016 Jun;48(6):634-9.
  48. Ramezani Tehrani F, Montazeri SA, Khalili D, Cheraghi L, Broekmans FJ, Momenan AA, de Kat AC, Azizi F. Age-specific anti-Müllerian hormone and electrocardiographic silent coronary artery disease. Climacteric. 2016 Aug;19(4):344-8
  49. Bagherzadeh-Khiabani F, Steyerberg EW, Khalili D*. THE AUTHORS REPLY to Letter to the Editor re: Bagherzadeh-Khiabani et al. J Clin Epidemiol. 2016 Jul;75:131-2.
  50. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016 Apr 9;387(10027):1513-30.
  51. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016 Apr 2;387(10026):1377-96.
  52. Khiabani FB, Ramezankhani A, Azizi F, Hadaegh F, Steyerberg EW, Khalili D*. A tutorial on variable selection for clinical prediction models: Feature selection methods in data-mining could improve the results. J Clin Epidemiol. 2016 Mar;71:76-85.
  53. Hadaegh F, Derakhshan A, Mozaffary A, Hasheminia M, Khalili D, Azizi F. Twelve-Year Cardiovascular and Mortality Risk in Relation to Smoking Habits in Type 2 Diabetic and Non-Diabetic Men: Tehran Lipid and Glucose Study. PLoS One. 2016 Mar 1;11(3):e0149780.
  54. Barzin M, Hosseinpanah, Motamedi MA, Shapoori P, Arian P, Daneshpour MA, Asghari G, Teymoornejad A, Eslamifar A, Khalili D, Jodeiri B, Alamdari S, Azizi F, Khalaj A.  Bariatric Surgery for Morbid Obesity: Tehran Obesity Treatment Study (TOTS) Rationale and Study Design. JMIR Res Protoc. 2016 Jan 20;5(1):e8.
  55. Afsharian S, Akbarpour S, Abdi H, Sheikholeslami F, Moeini AS, Khalili D, Momenan AA, Azizi F, Hadaegh F1. Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes: a 10 year follow-up: Tehran lipid and glucose study.  Diabetes Metab Res Rev. 2016 Sep;32(6):596-606.
  56. Asgari S, Khalili D, Mehrabi Y, Kazempour-Ardebili S, Azizi F, Hadaegh F. Incidence and risk factors of isolated systolic and diastolic hypertension: a 10 year follow-up of the Tehran Lipids and Glucose Study. Blood Press. 2016 Jun;25(3):177-83.
  57. Hadaegh F, Derakhshan A, Zafari N, Khalili D, Mirbolouk M, Saadat N, Azizi F. Pre-diabetes tsunami: incidence rates and risk factors of pre-diabetes and its different phenotypes over 9 years of follow-up. Diabet Med. 2015 Nov 25. doi: 10.1111/dme.13034. [Epub ahead of print]
  58. Masudi S, Yavari P, Mehrabi Y, Azizi F, Khalili D*. Underestimating the Effect of Lipids on Cardiovascular Events: Regression Dilution Bias in the Population-Based Cohort of Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2015 Oct 3;13(4):e27528.
  59. Hadaegh F, Hasheminia M, Abdi H, Khalili D, Bozorgmanesh M, Arshi B, Azizi F. Prehypertension Tsunami: A Decade Follow-Up of an Iranian Adult Population. PLoS One. 2015 Oct 6;10(10).
  60. Hashemi Nazari SS, Shakiba M, Khalili D*, Hadaegh F, Tohidi M, Azizi F. High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study. J Clin Lipidol. 2015 Jul-Aug;9(4):553-8.
  61. Masudi S, Yavari P, Mehrabi Y, Khalili D, Azizi F. Regression dilution bias in blood pressure and body mass index in a longitudinal population-based cohort study. J Res Health Sci. 2015 Spring;15(2):77-82.
  62. Kazemijaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Hosseinpanah F, Khalili D, Azizi F. The Prevalence and Causes of Primary Infertility in Iran: A Population-Based Study. Glob J Health Sci. 2015 Apr 19;7(6):45001.
  63. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, Azizi F, Cifkova R, Di Cesare M, Eriksen L, Farzadfar F, Ikeda N, Khalili D, Khang YH, Lanska V, León-Muñoz L, Magliano D, Msyamboza KP, Oh K, Rodríguez-Artalejo F, Rojas-Martinez R, Shaw JE, Stevens GA, Tolstrup J, Zhou B, Salomon JA, Ezzati M, Danaei G. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015 May;3(5):339-55.
  64. Azimi SS, Khalili D*, Hadaegh F, Yavari P, Mehrabi Y, Azizi F. Calculating population attributable fraction for cardiovascular risk factors using different methods in a population based cohort study. J Res Health Sci. 2015 Winter;15(1):22-7.
  65. Khalili M, Vasei M, Khalili D, Alimoghaddam K, Sadeghizadeh M, Mowla SJ. Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma. J Gastrointest Cancer. 2015 Sep;46(3):251-8.
  66. Khalili D, Asgari S, Hadaegh F, Steyerberg EW, Rahimi K, Fahimfar N, Azizi F. A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study. Int J Cardiol. 2015 Apr 1;184:587-94.
  67. Kazemi H, Ramezani Tehrani F, Minooee S, Khalili D, Azizi F. Women self-perception of excess hair growth, as a predictor of clinical hirsutism: a population-based study. J Endocrinol Invest. 2015 Aug;38(8):923-8.
  68. Derakhshan A, Tohidi M, Arshi B, Khalili D, Azizi F, Hadaegh F. Relationship of hyperinsulinaemia, insulin resistance and β-cell dysfunction with incident diabetes and pre-diabetes: the Tehran Lipid and Glucose Study. Diabet Med. 2015 Jan;32(1):24-32.
  69. Ayubi E, Khalili D*, Delpisheh A, Hadaegh F, Azizi F. Factor analysis of metabolic syndrome components and predicting type 2 diabetes: Results of 10-year follow-up in a Middle Eastern population. J Diabetes. 2015 Nov;7(6):830-8.
  70. Jahangiri-Noudeh Y, Akbarpour S, Lotfaliany M, Zafari N, Khalili D, Tohidi M, Mansournia MA, Azizi F, Hadaegh F. Trends in cardiovascular disease risk factors in people with and without diabetes mellitus: a Middle Eastern cohort study. PLoS One. 2014 Dec 2;9(12):e112639.
  71. Ramezankhani A, Pournik O, Shahrabi J, Azizi F, Hadaegh F, Khalili D*. The Impact of Oversampling with SMOTE on the Performance of 3 Classifiers in Prediction of Type 2 Diabetes. Med Decis Making. 2016 Jan;36(1):137-44.
  72. Ramezankhani A, Pournik O, Shahrabi J, Khalili D, Azizi F, Hadaegh F. Applying decision tree for identification of a low risk population for type 2 diabetes. Tehran Lipid and Glucose Study. Diabetes Res Clin Pract. 2014 Sep;105(3):391-8.
  73. Farahmand M, Ramezani Tehrani F, Simbar M, Mehrabi Y, Khalili D, Azizi F. Does metabolic syndrome or its components differ in naturally and surgically menopausal women? Climacteric. 2014 Aug;17(4):348-55.
  74. Kabir A, Khalili D. Built-in bias in HCV clearance in acute HCV infection. J Hepatol. 2014 Feb;60(2):461.
  75. Khalili D, Sheikholeslami FH, Bakhtiyari M, Azizi F, Momenan AA, Hadaegh F. The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: a 10-year population-based cohort study. PLoS One. 2014 Aug 27;9(8):e105804.
  76. Derakhshan A, Sardarinia M, Khalili D, Momenan AA, Azizi F, Hadaegh F. Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow-up: Tehran Lipid and Glucose Study. PLoS One. 2014 Jul 16;9(7):e102563.
  77. Panahi MH, Yavari P, Khalili D, Mehrabi Y, Hadaegh F, Azizi F. Obesity paradox: coronary heart disease incidence in patients with chronic kidney disease and metabolic syndromeIranian Journal of Epidemiology. 2015 Jun 15;11(1):72-81. (Persian Article)
  78. Panahi MH, Yavari P, Khalili D, Mehrabi Y, Hadaegh F, Azizi F. The Risk of Chronic Kidney Disease and Metabolic Syndrome in the Incidence of Coronary Heart Disease: Tehran Lipid and Glucose Study. Iranian Journal of Epidemiology. 2014 Mar 15;9(4):10-20. (Persian Article)
  79. Tohidi M, Bozorgmanesh M, Mohebi R, Khalili D, Saadat N, Khorrami N, Azizi F, Hadaegh F. Non-linear association between 25-hydroxyvitamin D and the incidence of type 2 diabetes: a community-based nested case-control study. Diabet Med. 2013 Aug;30(8):934-8.
  80. Samadi S, Bozorgmanesh M, Khalili D, Momenan A, Sheikholeslami F, Azizi F, Hadaegh F. Hypertriglyceridemic waist: the point of divergence for prediction of CVD vs. mortality: Tehran Lipid and Glucose Study. Int J Cardiol. 2013 May 10;165(2):260-5.
  81. Khalili D, Hadaegh F, Steyerberg EW. The authors reply. Am J Epidemiol. 2013 Apr 15;177(8):865-6.
  82. Jahangiri Noudeh Y, Hadaegh F, Vatankhah N, Momenan AA, Saadat N, Khalili D, Azizi F. Wrist circumference as a novel predictor of diabetes and prediabetes: results of cross-sectional and 8.8-year follow-up studies. J Clin Endocrinol Metab. 2013 Feb;98(2):777-84.
  83. Hadaegh F, Mohebi R, Khalili D, Hasheminia M, Sheikholeslami F, Azizi F. High normal blood pressure is an independent risk factor for cardiovascular disease among middle-aged but not in elderly populations: 9-year results of a population-based study. J Hum Hypertens. 2013 Jan;27(1):18-23.
  84. Mobasheri F, Khalili D, Mehrabi Y, Hadaegh F, Movahedi M, Momenan AA, Ghanbarian A, Zayeri F, Azizi F. Effects of Lifestyle Modification Education on Prevalence of General and Central Obesity in Adults: Tehran Lipid and Glucose Study" Journal of Isfahan Medical School. 2012;30:205. (Persian article)
  85. Azimi, S. S., Khalili D, Hadaegh F, Mehrabi Y, Yavari P, and Azizi F. Direct Estimate of Population Attributable Fraction of Risk Factors for Cardiovascular Diseases: Tehran Glucose and Lipid Study. Iranian Journal of Epidemiology. 2012;4:9-18. (Persian article)
  86. Mohammadreza B, Farzad H, Davoud K, Fereidoun A. Prognostic significance of the complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study. Cardiovasc Diabetol. 2012 Mar 7;11:20.  
  87. Khalili D, Hadaegh F, Fahimfar N, Shafiee G, Sheikholeslami F, Ghanbarian A, Azizi F. Does an electrocardiogram add predictive value to the rose angina questionnaire for future coronary heart disease? 10-year follow-up in a Middle East population. J Epidemiol Community Health. 2012 Dec;66(12):1104-9.
  88. Hadaegh F, Jahangiri Noudeh Y, Tohidi M, Vatankhah N, Khalili D, Mohebi R, Azizi F. Change in general and central adiposity measures in prediction of incident dysglycemia; Tehran Lipid and Glucose Study. Prev Med. 2012 Dec;55(6):608-12.
  89. Fahimfar N, Khalili D, Mohebi R, Azizi F, Hadaegh F. Risk factors for ischemic stroke; results from 9 years of follow-up in a population based cohort of Iran. BMC Neurol. 2012 Oct 2;12:117.
  90. Hatami M, Tohidi M, Mohebi R, Khalili D, Azizi F, Hadaegh F. Adolescent lipoprotein classifications according to National Health and Nutrition Examination Survey (NHANES) vs. National Cholesterol Education Program (NCEP) for predicting abnormal lipid levels in adulthood in a Middle East population. Lipids Health Dis. 2012 Aug 31;11:107.
  91. Khalili D, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study. Am J Epidemiol. 2012 Aug 1;176(3):177-86.
  92. Hadaegh F, Zabetian A, Khalili D, Safarkhani M, Philip T James W, Azizi F. A new approach to compare the predictive power of metabolic syndrome defined by a joint interim statement versus its components for incident cardiovascular disease in Middle East Caucasian residents in Tehran. J Epidemiol Community Health. 2012 May;66(5):427-32.
  93. Hatami M, Hadaegh F, Khalili D, Sheikholeslami F, Azizi F. Family history of diabetes modifies the effect of blood pressure for incident diabetes in Middle Eastern women: Tehran Lipid and Glucose Study. J Hum Hypertens. 2012 Feb;26(2):84-90.
  94. Karami M, Khalili D, Eshrati B. Estimating the proportion of diabetes to the attributable burden of cardiovascular diseases in Iran. Iran J Public Health. 2012;41(8):50-5.
  95. Tohidi M, Hasheminia M, Mohebi R, Khalili D, Hosseinpanah F, Yazdani B, Nasiri AA, Azizi F, Hadaegh F. Incidence of chronic kidney disease and its risk factors, results of over 10 year follow up in an Iranian cohort. PLoS One. 2012;7(9):e45304.
  96. Khalili D, Mosavi-Jarrahi A, Eskandari F, Mousavi-Jarrahi Y, Hadaegh F, Mohagheghi M, Azizi F. Evaluation of cause of deaths' validity using outcome measures from a prospective, population based cohort study in Tehran, Iran. PLoS One. 2012;7(2):e31427.
  97. Hadaegh F, Bozorgmanesh M, Safarkhani M, Khalili D, Azizi F. Predictability of body mass index for diabetes: affected by the presence of metabolic syndrome?. BMC Public Health. 2011 May 25;11:383.
  98. Solaymani-Dodaran M, Khalili D, Hosseini H, Najafi L, Kamali K, Ranjbar P, Tavakoli H, Ostovar A. Iranian Registry of Clinical Trials two years on and the timing of registrations. J Evid Based Med. 2011;4(3):168-71.
  99. Hadaegh F, Fahimfar N, Khalili D, Sheikholeslami F, Azizi F. New and known type 2 diabetes as coronary heart disease equivalent: results from 7.6 year follow up in a Middle East population. Cardiovasc Diabetol. 2010 Dec 4;9:84.
  100. Azizi F, Hadaegh F, Khalili D, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Zabetian A, Mehrabi Y, Kelishadi R, Aghajani H. Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. Arch Iran Med. 2010 Sep;13(5):426-8. 
  101. Azizi F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Mehrabi Y, Kelishadi R, Hadaegh F. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. Arch Iran Med. 2010 May;13(3):243-4.
  102. Hadaegh F, Zabetian A, Sarbakhsh P, Khalili D, James WP, Azizi F. Appropriate cutoff values of anthropometric variables to predict cardiovascular outcomes: 7.6 years follow-up in an Iranian population. Int J Obes (Lond). 2009 Dec;33(12):1437-45.
  103. Hadaegh F, Khalili D, Fahimfar N, Tohidi M, Eskandari F, Azizi F. Glucose intolerance and risk of cardiovascular disease in Iranian men and women: results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS). J Endocrinol Invest. 2009 Oct;32(9):724-30.
  104. Solaymani-Dodaran M, Ostovar A, Khalili D, Vasei M. Iranian Registry of Clinical Trials: path and challenges from conception to a World Health Organization primary register. J Evid Based Med. 2009 Feb;2(1):32-5.
  105. Hadaegh F, Khalili D, Ghasemi A, Tohidi M, Sheikholeslami F, Azizi F. Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. Nutr Metab Cardiovasc Dis. 2009 Jul;19(6):401-8.

 

Book Chapters (in Persian)

 

  1. Khalili D, Azizi F, Sadeghi-Hasanabadi A. An Introduction to Non-Communicable Diseases. In Azizi F, Janghorbani M, Hatami H. Epidemiology and Control of Common Diseases in Iran, Forth edition. Tehran: Khosravi press, 2017
  1. Delshad H, Khalili D, Azizi F. Diabetes. In Azizi F, Janghorbani M, Hatami H. Epidemiology and Control of Common Diseases in Iran, Forth edition. Tehran: Khosravi press, 2017
  1. Khalili D, Hadaegh F. Hypertension. In Yavari P. Epidemiology Textbook of Prevalent Diseases in Iran. Volume 2 – Noncommunicable Diseases. Tehran: Gapnashr, 2014
  1. Delshad H, Khalili D. Diabetes. In Yavari P. Epidemiology textbook of Prevalent Diseases in Iran. Volume 2 – Noncommunicable Diseases. Tehran: Gapnashr, 2014
  1. Hosseinpanah F, Barzin M, Khalili D. Obesity. In Yavari P. Epidemiology textbook of Prevalent Diseases in Iran. Volume 2 – Noncommunicable Diseases. Tehran: Gapnashr, 2014

 

International Conference Presentations

 

Year(s)

Title of presentation / Congress (Oral)

2018

Cost-Sensitive Measures Vs. Youden`s Index to Determine an Optimal Threshold for Biomarkers: A Practical Approach to Define Pre-Diabetes. SMDM 17th Biennial European Conference, Leiden, The Netherlands. (Oral)

2018

Score Risk Function to Predict Cardiovascular Disease Mortality in a Population Outside of Europe: Performance and Challenges. SMDM 17th Biennial European Conference, Leiden, The Netherlands. (Oral)

2018

Consistency between Score and Globorisk Prediction Models for Cardiovascular Disease Mortality in a Western Asian Country. SMDM 17th Biennial European Conference, Leiden, The Netherlands.

2018

Validation, Calibration, and Clinical Usefulness of FINDRISC, AUSDRISK, ADA Risk Scores for Predicting 5-year Incidence of Diagnosed Type 2 Diabetes in a Middle Eastern Population; the Tehran Lipid and Glucose study. SMDM 17th Biennial European Conference, Leiden, The Netherlands.

2016

A Novel Approach to Determine Potential Predictors of Diabetes Among Pre-Diabetic Women: A Population-Based Cohort Study. 17th International Congress of Endocrinology, Beijing, China.

2016

Incorporating Clinical Consequences to Screen for Pre-Diabetes: A Cost-Sensitive Cut-Off for Fasting Plasma Glucose. 17th International Congress of Endocrinology, Beijing, China.

2016

Cardiometabolic Mortality Rate Across Countries Is More Dependent on The Prevalence of Diabetes in Men Than on This Prevalence in Women: An Ecological Study. 17th International Congress of Endocrinology, Beijing, China.

2016

A New Approach to Metabolic Syndrome Components Using Latent Class Analysis (LCA): Dysglycemia Apart From Other Components. 17th International Congress of Endocrinology, Beijing, China.

2016

The Number Needed to Treat for Intensive Statin Therapy in Diabetic Men and Women According to 2013 ACC/AHA Guideline. 17th International Congress of Endocrinology, Beijing, China.

2015

A Systematic Approach to Variable Selection Methods Used In Data-Mining: A Practice in Epidemiology. European Congress in Epidemiology, Maastricht, The Netherlands. (Oral)

2015

Negative Interaction Between Chronic Kidney Disease and Metabolic Syndrome for Coronary Heart Disease Incidence in Non-Obese Individuals: Risk Factors Paradox. European Congress in Epidemiology, Maastricht, The Netherlands.

2015

Risk of Coronary Heart Events in Symptomatic and Asymptomatic Individuals: 10 Years Follow-Up in Tehran Lipid and Glucose Study (TLGS). European Congress in Epidemiology, Maastricht, The Netherland.

2015

Incidence of Recurrent CHD and the Impact of Obesity Paradox in a Population-Based Study: Tehran Lipid and Glucose Study. European Congress in Epidemiology, Maastricht, The Netherlands.

2015

Application of Net Benefit Fraction to Select Cut-Off for Medical Markers. European Congress in Epidemiology, Maastricht, The Netherlands.

2014

The Application of Risk Estimation in Guidelines for Statin Therapy. 10th International Congress of Endocrine Disorders, Tehran, Iran. (Oral)

2011

Net Benefit Fraction as a modified Population Attributable Fraction to evaluate the clinical performance of a risk function. 19th World Congress of Epidemiology, Edinburgh, Scotland.

2011

Clinical usefulness of Framingham Cardiovascular Risk Profile during a 10-year follow up in Iran. 19th World Congress of Epidemiology, Edinburgh, Scotland.

2011

An approach to compare the importance of different cardiovascular exposures as continuous variables. 19th World Congress of Epidemiology, Edinburgh, Scotland.

2011

Rose angina vs silent ischemia in prediction of coronary heart disease: Tehran Lipid and Glucose Study. 19th World Congress of Epidemiology, Edinburgh, Scotland.

2011

Different methods to calculate population attributable fraction of risk factors for cardiovascular diseases: Tehran Lipid and Glucose Study (TLGS). 19th World Congress of Epidemiology, Edinburgh, Scotland.

2011

Estimating the attributable burden of cardiovascular disease following reducing the prevalence of diabetes to theoretical and feasible minimum risk level. 19th World Congress of Epidemiology, Edinburgh, Scotland.

2009

Glucose intolerance and risk of cardiovascular disease in Iranian men and women. the 8th International Congress on Endocrine Disorders, Tehran, Iran. (Oral)

2009

Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in Iranian men population. 3rd International Congress on Prediabetes and the Metabolic Syndrome, Nice, France.